liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Interaction of PhXA41, a New Prostaglandin Analogue, With Pilocarpine: A Study on Patients With Elevated Intraocular Pressure
Linköping University, Department of Neuroscience and Locomotion, Ophthalmology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Neuroscience and Locomotion, Ophthalmology. Linköping University, Faculty of Health Sciences.
1993 (English)In: Archives of ophthalmology (1960), ISSN 0003-9950, Vol. 111, no 5, 662-665 p.Article in journal (Refereed) Published
Abstract [en]

Objective.  —To evaluate the effects of PhXA41, a new prostaglandin analogue, on the intraocular pressure (IOP) in patients receiving pilocarpine treatment and the effects of pilocarpine in patients receiving PhXA41 treatment.

Design.  —Twenty patients with ocular hypertension were randomized into two parallel groups. The treatment period was 2 weeks. Ten patients in group 1 were given PhXA41 twice daily during week 1 and, in addition, pilocarpine three times daily during week 2. Ten patients in group 2 received pilocarpine three times daily during week 1 and PhXA41 twice daily in addition during week 2. PhXA41 was used in a concentration of 0.006%, and pilocarpine was given in a concentration of 2%.

Main Outcome Measures.  —In group 1, the mean IOP on day 0 was 25.1 mm Hg; on day 7,19.1 mm Hg; and on day 14,17.6 mm Hg. In group 2, the mean IOP on day 0 was 23.8 mm Hg; on day 7,20.4 mm Hg; and on day 14,17.7 mm Hg.

Results.  —PhXA41 had a clinically significant IOP-lowering effect (23.4% reduction on day 7 as compared with baseline day (P<.001). The corresponding value with pilocarpine was 14.3% (P<.001). When pilocarpine was added to PhXA41, the additional IOP reduction was 7.4% (P<.01) compared with 14.2% (P<.01) when PhXA41 was added to pilocarpine. The two groups were found to have an almost equal reduction in IOP on day 14 (group 1,29.4%; group 2, 26.6%). No serious adverse reactions were seen. Some conjunctival hyperemia in the PhXA41-treated eyes was noted on day 7, as compared with the pilocarpine-treated eyes, but there were few complaints of discomfort.

Conclusions.  —This study indicated that PhXA41 could be useful in the treatment of glaucoma, as monotherapy, or in certain cases in combination with pilocarpine.

Place, publisher, year, edition, pages
1993. Vol. 111, no 5, 662-665 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-80119PubMedID: 8489450OAI: oai:DiVA.org:liu-80119DiVA: diva2:545686
Available from: 2012-08-21 Created: 2012-08-21 Last updated: 2017-12-07Bibliographically approved
In thesis
1. Aspects of the diagnosis and treatment of glaucoma
Open this publication in new window or tab >>Aspects of the diagnosis and treatment of glaucoma
2001 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Glaucoma is one of the most common causes of blindness in the world, and it is important that screening tests as well as treatment possibilities are improved continuously. A reliable but more rapid screening test than those already available would be of great interest. In addition, new and more effective treatment options would be most valuable. The aims of the present thesis were to evaluate the reliability of a new and rapid peripheral colour contrast sensitivity test as a tool for glaucoma screening and to gain more information on latanoprost, a recently developed prostaglandin analogue, in glaucoma treatment.

Colour contrast sensitivity was analysed with a system described by Arden and co-workers, using a computer controlled colour monitor. The test objects for the central test were letters of standard optotype subtending a visual angle of 3° . For the peripheral test, the test object was a colour contrasting annulus concentric with a fixation spot. The annulus had a radius of 12.5° in the extramacular field and a width of 1°. The colour contrast of the letter or the annulus in relation to the background could be changed, and a colour contrast threshold value could be obtained in the protan, deutan and tritan colour axes.

In a study of glaucoma patients, ocular hypertensive patients and normals, the peripheral colour contrast sensitivity test was found to distinguish the glaucoma patients from the normals. However, it was difficult to find a reliable cut-off point if the test is to be used as a screening test.

In a five-year prospective study of ocular hypertensive patients, the peripheral colour contrast sensitivity test could not clearly predict which patients would develop glaucoma and which would not, given that the Glaucoma Herrrifield Test is used as the golden standard. A change over time in the protan axis may, however, indicate glaucoma development. For a test to be used in glaucoma screening, it is necessary to know whether other common eye diseases such as diabetes and cataract affect the outcome. Therefore, the influence of diabetes and cataract on peripheral and central colour contrast sensitivity was also studied.

Diabetes type II was found to affect both peripheral and central colour contrast sensitivity, the tritan axis being the most affected one. For the tritan axis, the central colour contrast sensitivity seemed to correlate well with the degree of diabetic retinopathy, indicating the possibility of a new functional test of diabetic retinopathy.

Cataract, even moderately developed, affected both peripheral and central colour contrast sensitivity. Central colour contrast sensitivity seemed to be poorer in pseudophakic eyes than in normal eyes. Thus, both diabetes type II and moderate to severe cataract must be considered if the colour contrast sensitivity test is to be used for glaucoma screening. The choice of material for the IOL may also be of importance for postoperative central colour contrast sensitivity.

The prostaglandin analogue latanoprost effectively reduces the IOP at the original concentration of 0.005%. However, several patients need additional treatment. Therefore, the effect of pilocarpine in combination with latanoprost was studied. When pilocarpine was added to latanoprost, there was an additional reduction in the intraocular presure (IOP) (7.4%), and when latanoprost was added to pilocarpine the reduction was even more pronounced (142%). Therefore, it seems that latanoprost and pilocarpine can be combined in glaucoma treatment.

In certain eyes, an increased iris pigmentation was seen as a side-effect of latanoprost. This side-effect may be dose-dependent. Therefore, the original concentration of 0.005% was compared to a lower concentration, 0.001%. Latanoprost 0.005% was more effective than latanoprost 0.001% in reducing the IOP. However, the lower concentration was sufficiently effective to have a potential for clinical use in many patients. Latanoprost 0.005% gave an lOP reduction of 35% after four weeks of treatment, which was in agreement with earlier results. The lower concentration was, however, surprisingly effective and gave an IOP reduction of 27.7%.

Place, publisher, year, edition, pages
Linköping: Linköpings universitet, 2001. 49 p.
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 690
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-28033 (URN)12794 (Local ID)91-7219-983-0 (ISBN)12794 (Archive number)12794 (OAI)
Public defence
2001-10-05, Berzeliussalen, Universitetssjukhuset, Linköping, 13:00 (Swedish)
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2012-08-21Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedSummary

Authority records BETA

Friström, BjörnNilsson, Sven Erik G.

Search in DiVA

By author/editor
Friström, BjörnNilsson, Sven Erik G.
By organisation
OphthalmologyFaculty of Health Sciences
In the same journal
Archives of ophthalmology (1960)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 51 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf